Publication Name	World Journal of Psychiatry
Manuscript ID	64811
Country	India

Received	2021-02-23 18:15
Peer-Review Started	2021-02-24 10:57
To Make the First Decision
Return for Revision	2021-03-30 04:26
Revised	2021-04-12 16:50
Second Decision	2021-07-13 03:37
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-07-13 09:36
Articles in Press	2021-07-13 09:36
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-07-21 22:34
Typeset the Manuscript	2021-08-08 22:37
Publish the Manuscript Online	2021-08-12 08:46

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Review
Article Title	Clozapine resistant schizophrenia: Newer avenues of management
Manuscript Source	Invited Manuscript
All Author List	Subho Chakrabarti
ORCID	Author(s) ORCID Number Subho Chakrabarti http://orcid.org/0000-0001-6023-2194
Funding Agency and Grant Number
Corresponding Author	Subho Chakrabarti, MD, Professor, Department of Psychiatry, Postgraduate Institute of Medical Education and Research , Sector 12, Chandigarh 160012, India. subhochd@yahoo.com
Key Words	Clozapine-resistance; Augmentation; Medications; Electroconvulsive therapy; Psychosocial treatments; Schizophrenia
Core Tip	About 40%-70% of the patients develop clozapine-resistant schizophrenia (CRS), which has serious health, economic, and social consequences. Research on CRS has provided little support for the efficacy of psychotropics, electroconvulsive therapy, and cognitive-behavioural therapy in augmenting clozapine non-response. Therefore, newer approaches are needed including a clinical consensus about using the most effective of the currently available augmentation strategies. Augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions could also be tried. Finally, the best option at present may be to prevent clozapine resistance from developing by optimizing clozapine treatment and collaborating with patients and caregivers to ensure its continuation.
Publish Date	2021-08-12 08:46
Citation	Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatr 2021; 11(8): 429-448
URL	https://www.wjgnet.com/2220-3206/full/v11/i8/429.htm
DOI	https://dx.doi.org/10.5498/wjp.v11.i8.429

Full Article (PDF)	WJP-11-429.pdf
Full Article (Word)	WJP-11-429.docx
Manuscript File	64811-Review-Filipodia-CL.docx
Answering Reviewers	64811-Answering reviewers.pdf
Audio Core Tip	64811-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	64811-Conflict-of-interest statement.pdf
Copyright License Agreement	64811-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	64811-Language certificate.pdf
Peer-review Report	64811-Peer-review(s).pdf
Scientific Misconduct Check	64811-Bing-Wang JL-1.jpg
Scientific Misconduct Check	64811-Scientific misconduct check.pdf
Scientific Editor Work List	64811-Scientific editor work list.pdf
CrossCheck Report	64811-CrossCheck report.pdf